WVP
GYRE icon

Worth Venture Partners’s Gyre Therapeutics GYRE Stock Holding History

Worth Venture Partners’s Portfolio GYRE Stock Details GYRE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-13,240
Closed -$627K – 119
2020
Q4 		$627K Sell
13,240
-3,824
-22% -$166K 0.5% 55
2020
Q3 		$550K Hold
17,064
– – 0.45% 58
2020
Q2 		$751K Sell
17,064
-158
-0.9% -$7.42K 0.37% 39
2020
Q1 		$564K Buy
+17,222
New +$791K 0.35% 41

Other funds holding GYRE

NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return
GTC
Ghost Tree Capital New York $331M AUM 70.11% 1-Year Est. Return
ACP
Acuta Capital Partners Redwood City, California $142M AUM 783.79% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
2L
22NW LP Seattle, Washington $146M AUM 29.83% 1-Year Est. Return

Worth Venture Partners's GYRE Position: Q1 2021 in Review

Worth Venture Partners sold out of Gyre Therapeutics (GYRE) in Q1 2021, closing a stake of 13,240 shares — an estimated $627K sold.

Worth Venture Partners first reported a position in GYRE in Q1 2020 and held it in 4 quarters. The position peaked at $751K in Q2 2020. 89 funds tracked by Wall St. Rank hold GYRE as of Q1 2021.

  • Worth Venture Partners reported no remaining Gyre Therapeutics position as of Q1 2021 after selling out during the quarter.
  • Worth Venture Partners sold 13,240 Gyre Therapeutics shares in Q1 2021, an estimated $627K.
  • Worth Venture Partners first reported a position in Gyre Therapeutics in Q1 2020 and held it in 4 quarters.
  • Worth Venture Partners's Gyre Therapeutics position peaked at $751K in Q2 2020.
  • 89 funds tracked by Wall St. Rank held Gyre Therapeutics as of Q1 2021.

Based on Worth Venture Partners's 13F filing for Q1 2021, filed 17 May 2021.